Compare PBYI & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBYI | CYBN |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 280.9M |
| IPO Year | N/A | N/A |
| Metric | PBYI | CYBN |
|---|---|---|
| Price | $5.27 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 637.1K | 615.4K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $4.81 |
| 52 Week High | $6.12 | $10.80 |
| Indicator | PBYI | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 49.09 |
| Support Level | $4.84 | $5.50 |
| Resistance Level | $5.11 | $6.23 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 91.59 | 63.12 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.